Emerald
Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has filed
17 provisional US patent applications covering Emerald’s unique Defined
Dose™ cannabis dosage forms and formulations. Based on proprietary
Emerald research, these patent applications are contributing to
Emerald’s intellectual property portfolio and its intent to develop
distinctive cannabis products for medical-use and improved adult-use.
The products provide more precise and consistent delivery, dosage, and
formulations. Defined Dose™ cannabis products will, when made available
to the public, provide consumers with products currently not available.
The seventeen Defined Dose™ cannabis patent applications relate to:
- Inhaled dosage forms for smoking
- Inhaled dosage forms for vaping; and
- Capsule and edible formulations and dosage forms based on a novel understanding of cannabinoid molecular pathways and how they influence disease mechanisms.
Certain of the Defined Dose™
cannabis products are eligible for launch in Canada under existing
Canadian regulations. Others are expected to be eligible under
anticipated regulatory changes in 2019.
“We
expect significant potential cannabis market growth by offering adult
users and medical consumers consistent product characteristics, dosing
regimens, and alternative methods of consumption, with safety enhanced
through GMP-compliant production and enhanced product utility achieved
through knowledge of science. Emerald’s filing of these patent
applications is an important step,” said Chris Wagner, CEO of Emerald.
“Our expanding research and development effort is focused on internal
facilities and staff as well as forming key relationships with other
cannabis research experts, such as our recently announced agreement with
VivaCell Biotechologies Espana.”
“Emerald’s
intent is to be at the forefront of understanding the mechanism of
action of the endocannabinoid system and developing proprietary products
that enable both medical and adult-use consumers to achieve measured
outcomes with well characterized, reliable products,” said Avtar
Dhillion MD, Executive Chairman of Emerald. “Our aim is to produce a
product pipeline of next-wave cannabis products that fit the
better-defined needs and preferences of consumers as Canada and other
countries that legalize medical and recreational cannabis use.”
Although
cannabis is not presently federally legal in the United States for
commercial purposes, it is still the most important "first to file"
jurisdiction for intellectual property generation and protection
activity pertaining to cannabis and cannabinoids. The Patent Cooperation
Treaty permits Emerald to file Canadian and international versions of
these US patent applications in 152 member countries worldwide over the
coming year.
About Emerald Health Therapeutics, Inc.
Emerald
Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a
Licensed Producer under Canada’s Access to Cannabis for Medical
Purposes Regulations. Its 50%-owned Pure Sunfarms in BC is completing a
sophisticated 1.1 million square feet greenhouse; its Agro-Biotech
operation in Québec is completing a 75,000 square feet indoor facility.
Both facilities are in commercial production. It has also contracted for
approximately 500 acres of hemp harvest in 2018 and 1000 acres in 2019
to 2022 with the goal of extracting low-cost cannabidiol (CBD).
Emerald’s team is highly experienced in life sciences, product
development, large-scale agri-business, and marketing, and is focused on
developing proprietary, value-added cannabis products for medical and
adult-use customers. Emerald is part of the Emerald Health group,
which is broadly focused on developing pharmaceutical, botanical, and
nutraceutical products that may provide wellness and medical benefits by
interacting with the human body’s endocannabinoid system.
No comments:
Post a Comment